Background
Esketamine (brand name Spravato), manufactured by Janssen Pharmaceuticals, is the first and currently only FDA-approved ketamine-based medication specifically indicated for psychiatric use. Since its initial approval in March 2019, Spravato has undergone several regulatory updates, label expansions, and clinical milestones that reflect the evolving understanding of its role in mental health treatment.
This article provides a comprehensive overview of the key FDA actions and developments related to Spravato.
Timeline of FDA Actions
March 2019 — Initial Approval for Treatment-Resistant Depression
The FDA approved Spravato nasal spray for adults with treatment-resistant depression (TRD), defined as patients who have not responded to at least two adequate antidepressant trials. The approval was based on data from the TRANSFORM clinical trial program, which included three short-term studies and one long-term maintenance study.
Key aspects of the initial approval:
- Spravato must be used in conjunction with an oral antidepressant — it is not approved as monotherapy
- Administration is restricted to certified healthcare settings under the REMS program
- Patients must be monitored for at least 2 hours after each dose
- The initial dose is 56 mg, with the option to increase to 84 mg based on tolerability and response
The FDA granted Spravato a Breakthrough Therapy designation prior to approval, recognizing its potential to address a significant unmet medical need.
August 2020 — Expanded Indication for Suicidal Ideation
The FDA approved a new indication for Spravato: the short-term treatment of depressive symptoms in adults with major depressive disorder (MDD) who have current suicidal ideation with intent. This made Spravato one of the first medications specifically approved for this urgent clinical scenario.
The approval was based on two Phase 3 studies (ASPIRE I and ASPIRE II) in which patients experiencing a psychiatric emergency due to MDD with suicidal ideation received esketamine or placebo in addition to standard-of-care treatment. Patients who received esketamine showed rapid improvement in depressive symptoms within 24 hours, with the benefit maintained over the 4-week treatment period.
Ongoing Label Considerations
Since initial approval, the FDA has continued to review post-marketing safety data, real-world usage patterns, and additional clinical evidence. Areas of ongoing regulatory attention include:
- Long-term safety data from extended use studies
- Post-marketing adverse event reports
- Potential updates to the REMS program requirements
- Evaluation of whether any adjustments to dosing recommendations are warranted
The REMS Program in Practice
The Risk Evaluation and Mitigation Strategy (REMS) is a central component of Spravato's regulatory framework. It was implemented to mitigate risks associated with sedation, dissociation, and the potential for abuse and misuse.
Requirements for Healthcare Settings
To become certified to administer Spravato, healthcare settings must:
- Enroll in the Spravato REMS program
- Have trained healthcare professionals available to monitor patients
- Have the ability to manage acute adverse events, including severe sedation and hypertensive crises
- Maintain documentation of patient monitoring for each treatment session
Patient Experience Under REMS
For patients, the REMS requirements mean:
- Each treatment session requires a visit to a certified facility
- Self-administration of the nasal spray occurs under observation
- A 2-hour monitoring period follows each dose
- Patients cannot drive until the following day after restful sleep
- Enrollment in the REMS patient registry is required
While these requirements add logistical burden, they provide a structured safety framework that has contributed to a favorable post-marketing safety record.
Clinical Data Developments
Real-World Evidence
As Spravato has been used more broadly since its approval, real-world evidence has accumulated that complements the controlled clinical trial data:
- Real-world studies have generally confirmed the efficacy and safety profiles observed in clinical trials
- Some real-world analyses suggest that response rates in routine clinical practice may differ from those in controlled trials, reflecting the broader patient populations treated outside of strict inclusion/exclusion criteria
- Long-term follow-up data from observational studies continue to accumulate
Head-to-Head Comparisons
A question of significant clinical interest is how Spravato compares to generic IV racemic ketamine in terms of efficacy, cost-effectiveness, and patient preference. See our detailed racemic vs esketamine comparison for more. While no large, definitive head-to-head trial has been completed, several comparative studies and meta-analyses have begun to address this question:
- Some analyses suggest comparable antidepressant efficacy between IV racemic ketamine and intranasal esketamine
- Cost differences are significant — Spravato treatment is substantially more expensive than generic IV ketamine, though insurance coverage may offset this for some patients
- The convenience and standardization of Spravato may appeal to some patients and providers, while others prefer the flexibility and lower cost of IV ketamine
Insurance Coverage
One of the most significant practical developments since Spravato's approval has been the expansion of insurance coverage:
- Most major commercial insurers now cover Spravato — see our detailed guide on insurance coverage for ketamine, typically with prior authorization
- Medicare Part D covers Spravato for approved indications
- Medicaid coverage varies by state
- The manufacturer offers patient assistance programs for eligible patients
Prior authorization requirements typically involve documentation that the patient meets the definition of treatment-resistant depression and has failed specified numbers of antidepressant trials.
Looking Forward
Several developments on the horizon may influence the regulatory landscape for esketamine and ketamine-based treatments:
- Potential FDA consideration of R-ketamine (arketamine), which is being studied as a next-generation antidepressant with potentially fewer dissociative effects
- Possible modifications to the REMS program based on accumulated safety data
- Ongoing evaluation of esketamine for additional indications, including post-partum depression and anxiety disorders
- Continued evolution of clinical practice guidelines as the evidence base matures
The story of Spravato is still being written, and ongoing regulatory and clinical developments will continue to shape how this medication is used in the years ahead. For comprehensive treatment information, see the ketamine therapy guide.
References
- MedlinePlus: Esketamine Nasal Spray — National Library of Medicine drug information on Spravato, including FDA-approved indications and REMS requirements
- FDA: Drug Information — FDA resource on drug approvals, label updates, and post-marketing safety surveillance for esketamine
- StatPearls: Ketamine — Clinical reference covering esketamine pharmacology and its relationship to racemic ketamine
- NIMH: Depression — National Institute of Mental Health information on depression treatment, including FDA-approved options
Share